ArisGlobal has opened up new opportunities for clinical trial sponsors to use agDisclosure to meet trial registration and disclosure requirements at no cost.
ArisGlobal, a leading provider of solutions to the life science industry has opened up new opportunities for clinical trial sponsors to use agDisclosureTM to meet trial registration and disclosure requirements at no cost. With the release of agDisclosure™ Basic Edition, the company offers a free, entry-level version of its full product in support of trial registration and results disclosure to ClinicalTrials.gov.
agDisclosure Basic Edition is the first and only cloud-based offering that gives life science organizations a no-cost way to efficiently manage the trial registration and results disclosure process for ClinicalTrials.gov. Planning and tracking as well as configurable review and approval workflow functionality ensure the quality, consistency and integrity of data before it is submitted. Pre-recorded training and a user guide enable users to become productive quickly. Interested companies can learn more about this free version at http://totalclinical.com/agdisclosure-free-basic-edition.
“While there are good reasons for making the disclosure of protocol and results data mandatory, the increasing transparency requirements add to the administrative burdens around conducting clinical trials,” states Mathias Poensgen, Product Manager, ArisGlobal. “agDisclosure helps to keep these administrative costs under control by making the trial registration and disclosure process as efficient as possible. Using agDisclosure Basic Edition, companies can experience and evaluate the value this solution delivers over managing the disclosure process manually or using an in-house solution at no cost to their organization.”
The Basic Edition is an entry-level version of the agDisclosure Enterprise Edition, an extended solution that supports trial registration and results reporting to ClinicaTrials.gov, EudraCT and other global registries. The Enterprise Edition, (offered either on premise or hosted on the cloud), provides fuller functionality, including the ability to re-use one entry multiple times across different registries and seamless integration with any CTMS.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.